abstract |
The present invention relates to the production of stem cell-derived liver organoids and their use as a type 1 hemophilia cell therapy, and more specifically, the present invention relates to a vascular endothelial cell, a hepatic endoderm cell and By forming hepatic organoids of uniform size using mesenchymal stem cells, it can be used for the evaluation of hepatotoxicity of drugs related to various liver diseases including hemophilia and the development of new drugs. |